MX2021006886A - Dispersiones solidas amorfas. - Google Patents

Dispersiones solidas amorfas.

Info

Publication number
MX2021006886A
MX2021006886A MX2021006886A MX2021006886A MX2021006886A MX 2021006886 A MX2021006886 A MX 2021006886A MX 2021006886 A MX2021006886 A MX 2021006886A MX 2021006886 A MX2021006886 A MX 2021006886A MX 2021006886 A MX2021006886 A MX 2021006886A
Authority
MX
Mexico
Prior art keywords
amorphous solid
solid dispersions
utan
quinoxalin
pyrido
Prior art date
Application number
MX2021006886A
Other languages
English (en)
Spanish (es)
Inventor
Peng Li
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of MX2021006886A publication Critical patent/MX2021006886A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2021006886A 2018-12-14 2019-12-13 Dispersiones solidas amorfas. MX2021006886A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862779930P 2018-12-14 2018-12-14
PCT/US2019/066247 WO2020123952A1 (en) 2018-12-14 2019-12-13 Amorphous solid dispersions

Publications (1)

Publication Number Publication Date
MX2021006886A true MX2021006886A (es) 2021-09-14

Family

ID=71077112

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006886A MX2021006886A (es) 2018-12-14 2019-12-13 Dispersiones solidas amorfas.

Country Status (9)

Country Link
EP (1) EP3893878A4 (https=)
JP (1) JP7523440B2 (https=)
KR (1) KR20210103501A (https=)
CN (1) CN113473988A (https=)
AU (1) AU2019398451B2 (https=)
CA (1) CA3123085A1 (https=)
IL (1) IL283927A (https=)
MX (1) MX2021006886A (https=)
WO (1) WO2020123952A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112584837A (zh) * 2018-08-31 2021-03-30 细胞内治疗公司 新方法
CN115671057A (zh) 2022-10-19 2023-02-03 四川迈可隆生物科技有限公司 一种卢美哌隆药物组合物、长效微球缓释制剂及其制备方法
CN118566395B (zh) * 2024-08-02 2024-10-25 则正(济南)生物科技有限公司 测定甲苯磺酸卢美哌隆口崩片中杂质含量的方法、应用和系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4001281A1 (en) * 2016-08-09 2022-05-25 Teva Pharmaceuticals International GmbH Solid state forms of lumateperone ditosylate salt and preparation thereof
US11331316B2 (en) * 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
JP2020513023A (ja) * 2017-04-10 2020-04-30 ドクター・レディーズ・ラボラトリーズ・リミテッド ルマテペロンp−トシラートの非晶質形態および固体分散体
US11655251B2 (en) * 2017-11-27 2023-05-23 Egis Gyogyszergyar Zrt. Method for the production of lumateperone and its salts
CN112584837A (zh) * 2018-08-31 2021-03-30 细胞内治疗公司 新方法

Also Published As

Publication number Publication date
EP3893878A1 (en) 2021-10-20
IL283927A (en) 2021-07-29
JP7523440B2 (ja) 2024-07-26
JP2022512239A (ja) 2022-02-02
AU2019398451B2 (en) 2024-12-05
CA3123085A1 (en) 2020-06-18
EP3893878A4 (en) 2022-08-17
KR20210103501A (ko) 2021-08-23
WO2020123952A1 (en) 2020-06-18
AU2019398451A1 (en) 2021-07-15
CN113473988A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
MX2022010797A (es) Composiciones novedosas y metodos.
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
WO2019123294A3 (en) Pyrazolo piperidine and pyrazolo pyrimidine derivatives for the treatment of neuropsychiatric systemic lupus erythematosus
EP4488286A3 (en) Saccharide-polypeptide conjugate compositions and methods of use thereof
EP4599848A3 (en) Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY194619A (en) Glucocorticoid receptor agonist and immunoconjugates thereof
GEAP202014954A (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
AU2017265937A1 (en) Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
AU2017264697A1 (en) Combination treatment of ocular inflammatory disorders and diseases
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12017501816B1 (en) Azabenzimidazoles and their use as ampa receptor modulators
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
MX385336B (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
MX2021006886A (es) Dispersiones solidas amorfas.
MX383292B (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
GEP20247585B (en) Furoindazole derivatives
WO2018067520A3 (en) Therapeutic agents and methods:
EP4596543A3 (en) Farnesoid x receptor agonists and uses thereof